22 related articles for article (PubMed ID: 38575639)
1. Epigenetic Regulation in Urothelial Carcinoma.
Li K; Qi L; Tang G; Xu H; Li Z; Fan B; Li Z; Li Y
Curr Mol Med; 2024; 24(1):85-97. PubMed ID: 36545729
[TBL] [Abstract][Full Text] [Related]
2. EarlyTect BCD, a Streamlined PENK Methylation Test in Urine DNA, Effectively Detects Bladder Cancer in Patients with Hematuria.
Bang BR; Zhong J; Oh TJ; Lee JY; Seo Y; Woo MA; Lim JS; Na YG; Song KH; Shin JH; Lee JJ; Im CS; Kim S; Beqaj S; Shirk JD; Ke KW; Vallone J; An S
J Mol Diagn; 2024 Apr; ():. PubMed ID: 38677548
[TBL] [Abstract][Full Text] [Related]
3. Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study.
Chipollini J; Wright JR; Nwanosike H; Kepler CY; Batai K; Lee BR; Spiess PE; Stewart DB; Lamendella R
Urol Oncol; 2020 Jul; 38(7):615-621. PubMed ID: 32414567
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.
D'Costa JJ; Goldsmith JC; Wilson JS; Bryan RT; Ward DG
Bladder Cancer; 2016 Jul; 2(3):301-317. PubMed ID: 27500198
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients.
El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
Cancer Genet; 2022 Jan; 260-261():41-45. PubMed ID: 34922269
[TBL] [Abstract][Full Text] [Related]
8. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.
Yegin Z; Gunes S; Buyukalpelli R
DNA Cell Biol; 2013 Jul; 32(7):386-92. PubMed ID: 23682613
[TBL] [Abstract][Full Text] [Related]
10. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
Zhang C; Xu X; Wang T; Lu Y; Lu Z; Wang T; Pan Z
Sci Rep; 2024 Apr; 14(1):7941. PubMed ID: 38575639
[TBL] [Abstract][Full Text] [Related]
11. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
[TBL] [Abstract][Full Text] [Related]
12. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
